⚡ One LSD Dose. 12 Weeks of Change.

The Acid Test

LSD helped define the psychedelic conversation long before most modern clinical trials existed.

It was central to the counterculture of the 1960s. It shaped music, art, politics, spirituality, and the way an entire generation thought about consciousness.

But in the newer wave of psychedelic research, LSD has often received less attention than psilocybin, MDMA, and others.

To be fair, part of that is practical.

A full LSD experience can last eight to twelve hours. That means longer clinic days, more staff time, more monitoring, and a more expensive study design. And whether we like it or not, it still carries decades of cultural baggage.

Still, every time we make a post about it, we get messages from people who say LSD created lasting positive changes in their lives.

People talk about leaving behind destructive habits. Repairing old relationships. Seeing depression from a different angle. Feeling connected to life again after years of numbness.

It’s had a profound impact on me as well. After a reality-shattering wake up call LSD gave me in December of 2020, I lost over 100 lbs. and gave my entire life a positive makeover.

These stories are personal, not clinical proof in a modern scientific sense.

But they help explain why this new Phase 3 result from Definium Therapeutics feels bigger than a normal biotech headline.

The company’s treatment, DT120, produced a major depression result in a late-stage trial.

And the drug at the center of it is not a new LSD-like molecule.

It is a pharmaceutical form of LSD itself.

So what exactly is DT120? How does it compare to LSD-25? And could this be a sign that LSD is getting another serious look from modern medicine?

Behind the Tablet

Definium calls its treatment DT120 ODT.

ODT means orally disintegrating tablet. In simple terms, it is a tablet designed to dissolve quickly in the mouth rather than being swallowed like a conventional pill.

The active ingredient is lysergide D-tartrate.

Lysergide is the pharmaceutical name for LSD.

And LSD-25 is the historic name most people recognize: lysergic acid diethylamide.

The “25” comes from Albert Hofmann’s original laboratory work. LSD was the twenty-fifth compound in a series of lysergic acid derivatives he created while researching chemicals related to ergot fungus.

So is DT120 basically LSD-25?

Yes.

The active psychedelic drug in DT120 is lysergide, or LSD.

Definium has not invented a distant chemical cousin of LSD. It has not created a non-psychedelic version meant to avoid altered consciousness. And it is not a microdose product designed to sit below the threshold of a noticeable experience.

DT120 is a pharmaceutical formulation of LSD.

The “D-tartrate” part refers to the salt form used in the product.

That can sound like the company has transformed LSD into something completely different. It has not.

Salt forms are common in medicine. They can help make a compound more stable, easier to manufacture, easier to store, and more consistent in the way it is dosed and delivered.

The core active drug remains lysergide.

What Definium has built is a controlled medical product around that drug.

A known dose.

A known chemical identity.

A consistent formulation.

A defined treatment setting.

A clinical follow-up plan.

That is the real difference.

LSD, Rebuilt

The simplest way to understand the comparison is this:

LSD-25 is the molecule.

DT120 is the medical product built around the molecule.

At the active-drug level, they are the same psychedelic.

DT120 uses lysergide D-tartrate, delivered through a fast-dissolving tablet. The company says its formulation incorporates Catalent’s Zydis technology, which is designed to dissolve rapidly in the mouth.

Definium says this may offer a few practical advantages over a standard swallowed tablet: faster absorption, a quicker onset, improved bioavailability, and fewer gastrointestinal side effects.

Those are formulation goals.

They are not proof that the tablet turns LSD into a brand-new experience.

The trial tells us that Definium’s particular version of LSD, at a particular dose, in a particular clinical setting, produced a strong result for depression.

That is meaningful.

But the study is focused on one specific formulation, dose, and clinical setting. Its results give researchers a strong foundation to keep exploring how different LSD formats and doses may perform in the future.

Outside a medical setting, there can be uncertainty.

Dose can vary.

Purity can vary.

Storage can affect a compound.

Sometimes what is sold as LSD is something else entirely.

Then there is the setting itself. People may take it with no screening, no support, no plan, and no idea what to do if the experience becomes difficult.

DT120 is designed to remove as much of that uncertainty as possible.

It’s pharmaceutical-grade lysergide.

It’s given at a defined dose.

It’s used in a controlled environment.

And it comes with trained people in the room.

The molecule is old.

The medical framework around it is what is new.

One Long Afternoon

This was not a microdose study.

The 100-microgram dose used in Definium’s Emerge trial was intended to produce a full psychedelic experience.

Participants were monitored by trained attendants for up to eight hours.

That means this is not a medication people take with breakfast before heading to work.

It’s closer to a medical procedure.

A patient is screened ahead of time.

They come to a treatment site.

They take a measured dose.

They spend several hours in a supervised setting.

Then they are assessed and followed afterward.

Definium described the session plainly. Participants could experience changes in perception, intense thoughts, and strong emotions. The role of staff was to provide safety and grounding while the experience unfolded.

The average participant receiving DT120 met the company’s end-of-session criteria after 5.8 hours. The median was 5.1 hours. By hour eight, all participants had met those criteria.

That long duration has always been one of LSD’s biggest challenges in clinical research.

It’s hard to fit an eight-hour experience into the structure of a modern medical system.

A clinic needs dedicated rooms.

Staff need to be present for most of the day.

Patients need to plan around the session.

Trials become more expensive and more complicated to run.

That is part of why psilocybin has drawn so much attention. Its experience is still long, but generally shorter than LSD. The shorter experience is also one of the reasons both N,N-DMT and 5-MeO-DMT are soaring through research. LSD, for all its history and potency, has often been treated as the difficult one.

Too long.

Too intense.

Too politically loaded.

Too hard to package.

But those same qualities may be part of why people remember it so differently from conventional medication.

People often do not describe LSD as something that merely changed a symptom score.

They say it showed them something.

They say it gave them distance from an old story they had been trapped inside.

They say it made a relationship, a loss, an addiction, or a fear look different.

That does not mean every LSD experience is positive. It does not mean every intense experience is therapeutic.

But it helps explain why the idea of one carefully supported session creating a longer-lasting shift has always felt plausible to many people who have been there.

The Signal in the Data

The Emerge trial enrolled 149 adults between the ages of 18 and 74 with major depressive disorder.

Participants began with significant symptoms. Their average baseline MADRS score was 35.0 in the DT120 group and 34.0 in the placebo group.

MADRS is a common clinical scale used to track depression severity. It looks at symptoms like sadness, inner tension, sleep problems, appetite changes, concentration issues, pessimism, and suicidal thoughts.

At week six, people who received DT120 improved by an average of 13.3 points.

The placebo group improved by 5.2 points.

That created an 8.1-point placebo-adjusted difference, which was the trial’s main endpoint.

The early results were even more striking.

At week one, the DT120 group had improved by 17.6 points from baseline. The placebo group had improved by 3.4 points. That created a 14.2-point difference between the groups.

By week 12, the DT120 group was still showing a 7.3-point advantage over placebo.

The company also reported response and remission rates.

At six weeks, 35% of people who received DT120 had achieved at least a 50% reduction in depression symptoms.

Only 7% of the placebo group reached that level.

Twenty-four percent of people in the DT120 group reached remission, meaning their symptoms fell into a much lower clinical range.

Only 3% of people in the placebo group reached remission.

That is why the company’s CEO felt comfortable making such a big claim about the data.

It’s also why the result has drawn attention beyond the usual psychedelic world.

This was not a small exploratory study.

It was a randomized, double-blind, placebo-controlled Phase 3 trial across 20 sites.

There is still another pivotal depression study underway. But this result gives LSD something it has rarely had in the modern era:

A large, late-stage clinical data point that is difficult to dismiss.

From Counterculture to Clinic

There is a strange symmetry to this moment.

LSD entered the public imagination as a molecule that seemed impossible to control.

It moved through early psychiatric research, spiritual communities, music scenes, college campuses, and decades of political panic.

Then decades of regulation, stigma, and practical barriers made serious LSD research far harder to conduct.

Now, after years in the wilderness, it may be returning to medicine through a format that could hardly be more controlled.

A measured tablet.

A clinical trial.

A monitored room.

A structured protocol.

A depression scale.

A potential FDA submission.

Definium still has work to do.

The company’s second Phase 3 depression study, called Ascend, is ongoing. That study includes a 100-microgram dose, a 50-microgram dose, and placebo.

The lower dose is partly there to help deal with one of the hardest problems in psychedelic research: blinding.

When someone takes a strong psychedelic, they often know it.

That can shape expectations and influence how people report their symptoms.

The lower-dose group may make it harder for participants to confidently know which condition they were assigned to.

Definium is also continuing a 40-week open-label extension of Emerge, where eligible participants may receive DT120 based on the severity of their symptoms.

The company reported that DT120 was generally well tolerated. 99% of treatment-emergent adverse events were mild to moderate, transient, and mostly occurred on the day of dosing. Definium reported no serious adverse events and no increased signal for suicidal thoughts or behavior.

That is definitely encouraging.

The FDA still has to examine the full evidence.

But as many people in our comments often point out, there’s room for mixed emotions here.

A result like this is a real step forward, nobody is denying that.

It gives researchers more evidence to work with. It gives people living with depression another reason to hope. And it opens the door to the possibility that more people could one day find healing through a treatment that many outside the clinical system have already described as deeply meaningful.

At the same time, LSD remains a federally prohibited Schedule I substance in the United States. People can still be arrested, prosecuted, and have their lives ruined over it, even while pharmaceutical companies are running late-stage trials built around the same core drug that could result in a hefty profit.

That contradiction is hard to ignore.

Yes, research moving forward is truly worth celebrating.

But research alone is not the finish line.

There is still cultural work to do. Legal work to do. Educational work to do.

And there is still a larger conversation waiting to happen about why a compound can be treated as a promising psychiatric medicine in one room and a reason for punishment in another.

This moment is bigger than one company or one tablet.

LSD has spent decades being treated as either a dangerous cultural symbol or a fringe curiosity.

Meanwhile, people who have experienced its positive side have kept telling a different story.

They have talked about sobriety.

Forgiveness.

Creative rebirth.

Spiritual connection.

Relief from depression.

A renewed sense that life is worth participating in.

Those stories deserve science.

They deserve serious research.

They deserve a system capable of separating hype from real therapeutic potential.

And after decades of being pushed to the edge of medicine, LSD may finally be getting another chance to show what it can do when science gives it room to breathe.

✅ No one can stop you from seeing what’s delivered directly to your email. 

You’re already subscribed - congratulations!

You beat the algorithm 😉 

Thank you for joining us as we continue to navigate this ever-changing landscape.

P.S. Explore what they don’t want you to see - check us out on X (Twitter) and Instagram, and dive deeper into all things psychedelic on our website. 🌐✨